CClinicalTrials.gg
RecruitingNCT07666646Updated Aug 13, 2026

Comparison of M-TAPA and ESPB for Postoperative Pulmonary Function After Laparoscopic Cholecystectomy

An interventional study of Modified thoracoabdominal nerve block through the perichondrial approach (M-TAPA) and Erector spinae plane block (ESPB) in Pulmonary Function and Post Operative Pain Control, sponsored by Kayseri City Hospital. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-08-13.

Sponsored by Kayseri City Hospital · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

This prospective, randomized, controlled clinical trial aims to compare the effects of two ultrasound-guided fascial plane blocks, the Erector Spinae Plane Block (ESPB) and the Modified Thoracoabdominal Nerve Block through Perichondrial Approach (M-TAPA), on postoperative pulmonary function and analgesic consumption in patients undergoing laparoscopic cholecystectomy. Laparoscopic cholecystectomy is one of the most frequently performed abdominal surgical procedures worldwide. Despite minimally invasive techniques, postoperative pain remains a significant clinical problem due to port-site trauma, pneumoperitoneum, diaphragmatic irritation, and visceral manipulation.

Inadequate pain control may lead to impaired respiratory mechanics, reduced mobilization, delayed recovery, and an increased risk of postoperative pulmonary complications. Postoperative pulmonary dysfunction is a common consequence of upper abdominal surgery and may persist for several days, contributing to reductions in forced vital capacity (FVC) and forced expiratory volume in one second (FEV1), which are associated with increased postoperative morbidity.

Although opioid-based analgesia is widely used, it is associated with adverse effects such as respiratory depression, nausea, vomiting, ileus, and delayed recovery. Therefore, regional anesthesia techniques and multimodal analgesia strategies are increasingly recommended to reduce opioid consumption while improving pain control.

ESPB and M-TAPA are ultrasound-guided fascial plane blocks used for postoperative analgesia in abdominal surgery. ESPB provides somatic and visceral analgesia through the spread of local anesthetic affecting the spinal nerve rami, while M-TAPA targets the anterior branches of the thoracoabdominal nerves to provide extensive anterior and lateral abdominal wall analgesia.

Despite their increasing use, there is limited high-quality comparative evidence evaluating the effects of ESPB and M-TAPA on postoperative pulmonary function and opioid consumption in laparoscopic cholecystectomy. This study compares these two regional anesthesia techniques in a randomized controlled design to evaluate their impact on postoperative respiratory function and analgesic requirements.

Read the detailed description

This study is a prospective, randomized, controlled clinical trial designed to compare the effects of two ultrasound-guided fascial plane blocks, the Erector Spinae Plane Block (ESPB) and the Modified Thoracoabdominal Nerve Block through Perichondrial Approach (M-TAPA), on postoperative pulmonary function and analgesic consumption in patients undergoing laparoscopic cholecystectomy.

A total of 60 patients will be randomly allocated into two groups: ESPB group (n=30) and M-TAPA group (n=30). All patients will undergo standard general anesthesia. After induction of general anesthesia and before surgical incision, regional blocks will be performed.

Patients in the ESPB group will receive bilateral ultrasound-guided erector spinae plane block at the T9 vertebral level using 0.25% bupivacaine, 20 mL per side (total 40 mL). Patients in the M-TAPA group will receive bilateral ultrasound-guided modified thoracoabdominal nerve block through the perichondrial approach using the same concentration and volume of local anesthetic (0.25% bupivacaine, total 40 mL).

All blocks will be performed under sterile conditions using a high-frequency linear ultrasound probe and an 80 mm echogenic needle.

All patients will receive standardized multimodal analgesia, including intravenous paracetamol (1 g every 8 hours) and intravenous ibuprofen (400 mg every 12 hours) for 24 hours postoperatively. The first doses of paracetamol and ibuprofen will be administered 10 minutes before the end of surgery.

Postoperative pain will be assessed using the Numeric Rating Scale (NRS) at rest and during movement at 1, 6, 12, 18, and 24 hours after surgery. Patient-controlled analgesia (PCA) with morphine will be used for postoperative analgesia. The PCA device will be set to deliver 1 mg morphine boluses with a lockout interval of 15 minutes and a maximum dose of 96 mg within 24 hours. Rescue analgesia with intravenous fentanyl (25 mcg) will be administered in patients with persistent pain (NRS ≥4 despite PCA bolus).

Total opioid consumption will be calculated as cumulative morphine consumption within the first 24 postoperative hours.

Pulmonary function tests will be performed preoperatively and at 1, 6, and 24 hours postoperatively, including forced vital capacity (FVC), forced expiratory volume in one second (FEV1), FEV1/FVC ratio, and peak expiratory flow (PEF).

Postoperative recovery quality will be evaluated using the Quality of Recovery-15 (QoR-15) questionnaire at 24 hours after surgery.

02

Conditions studied

  • Pulmonary Function
  • Post Operative Pain Control
03

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Patients aged 18-70 years
  • American Society of Anesthesiologists (ASA) physical status I-III
  • Patients scheduled for elective laparoscopic cholecystectomy
  • Patients who provide written informed consent
  • Patients who are able to cooperate and perform pulmonary function tests (PFTs)

Exclusion criteria

Exclusion Criteria:

  • Coagulation disorders or anticoagulant therapy contraindicating regional anesthesia
  • Infection at the planned block site
  • Known allergy to local anesthetic agents
  • Conversion to open surgery
  • Hemodynamic instability
  • Inability to cooperate with pulmonary function tests (PFTs)
  • Pre-existing severe pulmonary disease (e.g., severe chronic obstructive pulmonary disease or restrictive lung disease)
  • Chronic opioid use or opioid dependence
  • Pregnancy or breastfeeding
  • Active smokers
  • Body mass index (BMI) > 35 kg/m²
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    M-TAPA Block

    An ultrasound-guided modified thoracoabdominal nerve block through the perichondrial approach (M-TAPA) performed bilaterally with local anesthetic for postoperative analgesia after laparoscopic cholecystectomy.

    Procedure: Modified thoracoabdominal nerve block through the perichondrial approach (M-TAPA)

  • Experimental
    Erector spinae plane block (ESPB)

    An ultrasound-guided erector spinae plane block (ESPB) performed with local anesthetic for postoperative analgesia after laparoscopic cholecystectomy.

    Procedure: Erector spinae plane block (ESPB)

Interventions

  • ProcedureModified thoracoabdominal nerve block through the perichondrial approach (M-TAPA)

    An ultrasound-guided modified thoracoabdominal nerve block through the perichondrial approach (M-TAPA) was performed bilaterally under sterile conditions. The ultrasound transducer was placed in the sagittal plane at the 9th-10th rib level. The probe was angled to visualize the underside of the costal margin. After identification of the target fascial plane, an echogenic needle was advanced in-plane until the tip was positioned beneath the costal cartilage. Hydrodissection with 5 mL of saline was used to confirm correct needle placement. Following confirmation, 20 mL of 0.25% bupivacaine was administered on each side, for a total volume of 40 mL. Blocks were performed under ultrasound guidance using an 80 mm echogenic needle and a 6-10 MHz linear transducer.

  • ProcedureErector spinae plane block (ESPB)

    An ultrasound-guided erector spinae plane block (ESPB) was performed bilaterally at the T9 vertebral level under sterile conditions. A high-frequency linear ultrasound probe (6-10 MHz) was used to identify the erector spinae muscle and transverse process. An 80 mm echogenic needle was advanced in-plane in a cranio-caudal direction until the tip was positioned in the fascial plane deep to the erector spinae muscle. Hydrodissection with saline was used to confirm correct needle placement, followed by administration of 20 mL of 0.25% bupivacaine on each side, for a total volume of 40 mL.

05

What researchers measure

Primary outcomes

  1. Forced Expiratory Volume in 1 Second (FEV1)

    Forced expiratory volume in one second (FEV1, liters) will be measured to assess postoperative pulmonary function.

    Time frame: Preoperatively (baseline), and at 1, 6, and 24 hours postoperatively.

  2. Forced Vital Capacity (FVC)

    Forced vital capacity (FVC, liters) will be measured to assess postoperative pulmonary function.

    Time frame: Preoperatively (baseline), and at 1, 6, and 24 hours postoperatively.

  3. FEV1/FVC Ratio

    The FEV1/FVC ratio (percentage, %) will be measured to assess postoperative pulmonary function.

    Time frame: Preoperatively (baseline), and at 1, 6, and 24 hours postoperatively.

  4. Peak Expiratory Flow (PEF)

    Peak expiratory flow (PEF, liters/minute) will be measured to assess postoperative pulmonary function.

    Time frame: Preoperatively (baseline), and at 1, 6, and 24 hours postoperatively.

Secondary outcomes

  1. Total Opioid Consumption

    Total opioid consumption will be calculated as cumulative morphine dose delivered via patient-controlled analgesia (PCA) and rescue analgesic requirements during the first 24 postoperative hours.

    Time frame: First 24 postoperative hours

  2. Postoperative Pain Scores (NRS)

    Postoperative pain intensity will be assessed using the Numeric Rating Scale (NRS) at rest (static) and during movement (dynamic). (Scores range from 0 to 10, where 0 indicates no pain and 10 indicates the worst possible pain)

    Time frame: Postoperative 1st, 6th, 12th, 18th, and 24th hours

  3. Quality of Recovery-15 (QoR-15)

    Postoperative recovery quality will be assessed using the Quality of Recovery-15 (QoR-15) questionnaire. (Scores range from 0 to 150, where 0 indicates the worst possible recovery and 150 indicates the excellent/best possible recovery)

    Time frame: 24 hours postoperatively

06

Study locations

1 of 1 sites recruiting
  • Kayseri City Hospital
    Kayseri, Kocasinan 38080, Turkey (Türkiye)
    Recruiting
07

References and documents

Individual participant data

Plan to share: Undecided — Anonymized participant-level data, including demographic variables, pulmonary function tests, pain scores, opioid consumption, and QoR-15 outcomes, may be shared upon reasonable request.

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT07666646
Lead sponsor
Kayseri City Hospital
Responsible party
Muhammed Nail Tekcan (Medical Doctor, Department of Anesthesiology and Reanimation, Kayseri City Hospital) — Principal investigator
First posted
Jun 24, 2026
Start date
Aug 11, 2026
Primary completion
Jan 1, 2027 (estimated)
Completion
Mar 1, 2027 (estimated)
Last update
Aug 13, 2026

Study contacts

Muhammed N Tekcan, Anesthesiology and Reanimation
Contact
mntekcan@gmail.com
+905387931833

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion